Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Metwalli Website

Adam R. Metwalli, M.D.

Portait Photo of Adam Metwalli
Urologic Oncology Branch
Staff Clinician
Center for Cancer Research
National Cancer Institute
Building 10, CRC, Room 2W-5940
Bethesda, MD 20892
Phone:  
301-496-6353
Fax:  
301-402-0922
E-Mail:  
metwallia@mail.nih.gov

Biography

Dr. Metwalli is a Senior Clinical Staff and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. Dr. Metwalli is a graduate of Wake Forest University School of Medicine and completed a surgical internship at the University of Louisville Hospital before completing a urology residency at the Oklahoma University Medical Center. Dr. Metwalli then completed a total of 3 years of urologic oncology fellowship with 2 years of translational research in the Department of Urology at U.T. M.D. Anderson Cancer Center in Houston, TX. He then completed a clinical fellowship year within the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, MD. After completing his fellowship, Dr. Metwalli spent 3 years in private practice as a urologic oncologist for a large single specialty group before returning to the Urologic Oncology Branch of the National Cancer Institute as a faculty member. Clinically, Dr. Metwalli specializes in complex renal surgery including robotic, laparoscopic and open partial nephrectomies for multifocal tumors as well as surgical approaches for bladder, prostate and penile carcinoma.

Dr. Metwalli is an active member of the Society of Urologic Oncology, the American Urological Association, the American College of Surgeons, and a member of the Medical Advisory Board for the National Kidney Foundation--Maryland.

Research

Dr. Metwalli's research interests are in apoptosis pathways in kidney, bladder and prostate cancer. His previous research involved sensitizing urothelial and prostate carcinoma cells to TRAIL-induced apoptosis using small molecule analogs of Second Mitochondrial Activators of Caspases (SMAC) as well as chemotherapy and interferon. He also has an interest in the androgen pathways in normal and neoplastic prostate cancer with a specific emphasis on the enzymatic function of 3-alpha-hydroxysteroid dehydrogenase (AKR1C3) and the androgen receptor.

This page was last updated on 3/6/2014.